Esketamine combined with an SNRI is more effective for treatment-resistant depression (TRD) than when paired with an SSRI. Analysis of over 55,000 patients showed that the SNRI combination ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

More information: Jennifer Kern Sliwa et al, Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery ...

Esketamine is a more potent form of ketamine, an anesthetic that doctors have used for many years to treat depression. The nasal spray, from Janssen Pharmaceuticals, ...

Since esketamine has mind-altering properties, it comes with warnings about risks of abuse and misuse. The fact that you can’t take it home is good news for its safety.

Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 ...

Esketamine administered intravenously during elective cesarean delivery may significantly reduce depressive symptoms in the early postpartum period, according to study results published in JAMA ...

Ketamine or more specifically, its cousin — esketamine — has started to change the landscape of depression, especially where it borders on suicide. Ketamine may help severely depressed, study ...

Esketamine-treated women had lower EPDS scores on day seven and 42 (median difference, -3). Individuals receiving esketamine also had reduced HDRS scores 42 days after delivery (mean difference, -4).

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found.

Esketamine nasal spray, a rapid-acting anti-depressant, is known to be effective against TRD when administered alongside antidepressants like selective serotonin reuptake inhibitor (SSRI) or a ...